TNFRSF17 may promote plasma cell survival and contribute to LN pathogenesis, and the targeted drug IBI379 effectively induces apoptosis in plasma cells without affecting B cells in LN patients. The gene discussed is TNFRSF17; the disease is lobular neoplasia.